UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2013
Commission File Number: 001-34541
CHINA
CORD BLOOD CORPORATION
(Translation of registrant’s name into English)
48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.
This report and each of the exhibits to this report are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-168873 and No. 333-183143) of the Company.
Completion of Acquisition or Disposition of Assets
On February 7, 2013, Favorable Fort Limited (“Favorable Fort”), an indirect non-wholly owned subsidiary of China Cord Blood Corporation (the “Company”), consummated the transaction provided for in a shares purchase agreement (the “Purchase Agreement”) with Cordlife Services (S) Pte. Ltd., a company limited by shares incorporated in Singapore (“Cordlife Services”), pursuant to which Favorable Fort repurchased the 17% of its outstanding ordinary shares not already indirectly owned by the Company from Cordlife Services for a total purchase price of approximately $8.65 million. As a result of such repurchase, Favorable Fort is now an indirect wholly owned subsidiary of the Company.
This transaction was initially disclosed in the Company’s Report of Foreign Issuer on Form 6-K furnished to the SEC on December 6, 2012.
Other Events
On February 7, 2013, the Company issued a press release announcing the closing of the transaction. A copy of the press release is attached hereto as exhibit 15.1.
Exhibits
| Exhibit No. | Description | |
| 15.1 | Press release, dated February 7, 2013 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHINA CORD BLOOD CORPORATION | |||
| By: | /s/ Albert Chen | ||
| Name: | Albert Chen | ||
| Title: | Chief Financial Officer | ||
Dated: February 7, 2013
Exhibit Index:
| Exhibit No. | Description | |
| 15.1 | Press release, dated February 7, 2013 |
China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
HONG KONG, China, February 7, 2013 -- China Cord Blood Corporation (NYSE:CO) (“CCBC” or the “Company”), the first and largest cord blood banking operator in China, today announced the completion of the previously announced transaction with Cordlife Services (S) Pte. Ltd., a subsidiary of the Company’s strategic affiliate, Cordlife Limited (CBB.AU) (“Cordlife”), a cord blood and tissue banking services provider listed on the Australian Securities Exchange. As a result of the transaction, CCBC’s effective equity interest in Shandong Province Qilu Stem Cells Engineering Co., Ltd. (“Qilu”), the operator of the Shandong Cord Blood Bank, has increased from approximately 19.9% to 24.0%, further extending the Company’s presence in the Shandong market. The transaction was first announced on December 6, 2012.
For further details of the transaction, please refer to CCBC’s Report on Form 6-K filed on December 6, 2012 with the US Securities and Exchange Commission, which contains copies of the related documents and is available at http://www.sec.gov.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: [email protected]
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5185
Email: [email protected]